PARIS, Sept 25 (Reuters) - Ipsen has submitted a six-month sustained version of its prostate cancer treatment Decapeptyl for marketing approval with European health authorities, the French drugmaker ...
PARIS, Oct 13 (Reuters) - Ipsen has completed the marketing approval registration in nine European countries for a six-month sustained version of prostate cancer treatment Decapeptyl, the French ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback